xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

288

KUANetal.

TABLE XXV.5 (Continued)

Clinical endpoints

Study

Year LOE Study design Study groups

Conclusion

1. No significant difference in cumulative incidence of grade 3–4 acute or late toxicities between SEQ versus SIB group 2. Significant improved 3-year RPFS in SIB group compared with SEQ group 3. No significant differences in SEQ versus SIB group for complete response rate, 3-year PFS, and 3-year OS, PFS, LPFS, andDMFS

1. Acute and

209 NPC patients treated with CRT to T2–4 or positive nodal disease for maximum seven cycles + adjuvant chemotherapySEQ IMRT - two plans: 2 Gy × 25 Fr to low-risk PTV, followed by sequential boost (2Gy × 10Fr) to high-risk PTV SIB-IMRT - 56 Gy to low-risk PTV and 70 Gy to high-risk PTV, in 33 Fr 616 NPC patients IMRT versus 2DRT Chemotherapy for stage III and IV if not contraindicated

Lertbutsayanukul et al. 1676

2018 2

Randomized phase II/III study

late toxicities

2. 3-year PFS andOS 3. LPFS, RPFS, DMFS

Penget al. 1670

2012 2

Prospective RCT

1. 5-year LRC, OS 2. Acute and late toxicity

1. IMRT group had higher LRC rate compared with 2DRT, yet the difference was only significant in T4 after disease stage stratification 2. IMRT group had higher RC rate compared with 2DRT and the difference was only significant in N2 disease 3. IMRT group had higher OS rate compared with 2DRT and the difference was significant in stage III and N2 disease 4. More frequent acute toxicities were observed in 2DRT group (acute hearing loss, xerostomia) and also for late toxicities (cranial nerve palsy, trismus, neck fibrosis, xerostomia, and hearing loss) 1. Proton therapy had similar 2-year LRFS, PFS, and OS compared with IMRT 2. Significantly lower mucositis and feeding tube rates in proton therapy group versus IMRT 3. All other acute and late effects

Lee et al. 1678

1. 2-year LRFS, PFS, andOS 2. Acute and late toxicities

2021 2

Systematic review

369 patients in nine retrospective studies Comparison of proton versus photon therapy, concurrent chemotherapy used for all studies

were improved with proton therapy, but not statistically significant

(Continues)